1st International Electronic Conference on Biomedicine
Part of the International Electronic Conference on Biomedicines series
1–26 Jun 2021
Therapeutic Targets, Therapeutic Strategies, Naturally Driven Biomedicines, Pharmaceuticals, Biopharmaceutical Products
- Go to the Sessions
-
- S1. Nanomedicine and Precision Medicine
- S2. Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
- S3. Cancer Therapeutics
- S4. Metal-based Therapeutics in Preclinical and Clinical Developments
- S5. Oncolytic Virus-Mediated Immunotherapy
- S6. Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
- S7. Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
- S8. Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
- S9. Translational Biomarkers in Clinical Biomedicine and Precision Medicine
- S10. G-protein-coupled Receptor Family
- S11. Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
- Event Details
ECB 2021 has been a success! Welcome to the new electronic conference ECB 2023.
Welcome from the Chairs
Dear Colleagues,
It is my pleasure to invite you to join the 1st International Electronic Conference on Biomedicine (ECB 2021) that is hosted online by: https://ecb2021.sciforum.net.
ECB 2021 will present the latest research related to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products.
Topics of interest include but are not limited to:
- Nanomedicine and Precision Medicine
- Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
- Cancer Therapeutics
- Metal-based Therapeutics in Preclinical and Clinical Developments
- Oncolytic Virus-mediated Immunotherapy
- Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
- Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
- Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
- Translational Biomarkers in Clinical Biomedicine and Precision Medicine
- G-protein-coupled Receptor Family
- Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
ECB 2021 seeks to fulfill this need by offering a completely digital (online) method for running a scientific conference. ECB 2021 will allow its participants to share their latest research results and receive near-instantaneous feedback from biomedical researchers throughout the world through online question and answer sessions and discussion groups. In this way, ECB 2021 will serve as a platform for advancing the state-of-the-art in biomedicines. There is no cost to participate in ECB 2021.
All submitted abstracts will be evaluated by the conference committee. Upon acceptance of their abstract, authors will contribute an extended abstract for the conference proceedings and a slide presentation of their work. Selected papers (need 50% extension compared with the proceedings papers) will be considered for publication in the special issue "Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)", with a 20% discount on the APC after peer-review.
I hope you will choose to be a part of this exciting conference and present your most transformative research on biomedicine.
Conference Secretariat
Ms. Nicole Peng
MDPI Branch Office, Wuhan
E-mail: ecb2021@mdpi.com
Ms. Penny Zhang
MDPI Branch Office, Wuhan
E-mail: ecb2021@mdpi.com
Ms. Stefanie Li
MDPI Branch Office, Wuhan
E-mail: ecb2021@mdpi.com
Conference Chairs
Albany College of Pharmacy and Health Sciences, Rensselaer, USA
Faculté de Pharmacie, Paris, France
Conference Committee
Albany College of Pharmacy and Health Sciences, Rensselaer, USA
The University of Auckland, Auckland, New Zealand
The University of Pittsburgh Cancer Institute, and University of Pittsburgh School of Medicine, Pittsburgh, USA
McMaster University, Ontario, Canada
University of Szeged, Szeged, Hungary
The London BioScience Innovation Centre, London, United Kingdom
Alborg University, Aalborg, Denmark
The University of British Columbia, Vancouver, Canada
Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy
Session Chairs
Professor Shaker A. Mousa
Albany College of Pharmacy and Health Sciences, Rensselaer, USA
Nanomedicine and Precision Medicine; Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
Dr. Veronique Baud
Faculté de Pharmacie, Paris, France
Cancer Therapeutics
Dr. Muhammad Hanif
The University of Auckland, Auckland, New Zealand
Metal-based Therapeutics in Preclinical and Clinical Developments
Dr. Zong Sheng Guo
The University of Pittsburgh Cancer Institute, and University of Pittsburgh School of Medicine, Pittsburgh, USA
Oncolytic Virus-Mediated Immunotherapy
Dr. Jacek M. Kwiecien
McMaster University, Ontario, Canada
Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
Dr. Masaru Tanaka
University of Szeged, Szeged, Hungary
Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
Professor Alexander Seifalian
The London BioScience Innovation Centre, London, United Kingdom
Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
Dr. Allan Stensballe
Alborg University, Aalborg, Denmark
Translational Biomarkers in Clinical Biomedicine and Precision Medicine
Professor Ujendra Kumar
The University of British Columbia, Vancouver, Canada
G-protein-coupled Receptor Family
Professor Ciro Isidoro
Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy
Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
Invited Speakers
1. Department of Surgery, Drexel University College of Medicine, Pittsburgh, PA 15212, USA
2. AHN Cancer Institute
Sessions
S2. Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
S3. Cancer Therapeutics
S4. Metal-based Therapeutics in Preclinical and Clinical Developments
S5. Oncolytic Virus-Mediated Immunotherapy
S6. Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
S7. Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
S8. Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
S9. Translational Biomarkers in Clinical Biomedicine and Precision Medicine
S10. G-protein-coupled Receptor Family
S11. Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
Video from Invited Speaker
Oncolytic Virus-Mediated Immunotherapy
by Prof.Dr. David Bartlett
List of accepted submissions (50)
Id | Title | Authors | Presentation Video | Poster PDF | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-041743 | Structural analyses of metallodrug/β-lactoglobulin adducts for rational design of new biomaterials | , , |
Show Abstract |
||||||||||||||||||||||||||||||||||||||
β-lactoglobulin (BLG) is a whey carrier protein of 18.4 kDa. This protein is a good system for the preparation of micro- or nanoparticles for pharmaceutical industry because of its high solubility, safe status, biodegradable nature, gel forming ability, abundance, stability at acidic pH and against gastric pepsin. It has been shown that BLG can bind anticancer Pt-based drugs and that BLG–pectin nanoparticles can transfer cytotoxic Pt compounds to cancer cells. To study the molecular basis of the Pt-based drug recognition by BLG, we have analyzed the interaction of this protein with two extensively used anticancer metallodrugs, i.e. cisplatin and oxaliplatin, both in solution and at solid state. Structural data reveal that cisplatin binds BLG coordinating Met7, His146 and Lys8 side chains, without affecting the overall 3D structure. The molecular structure of the adduct formed upon reaction of oxaliplatin with BLG suggests the existence of a single Pt binding site. Circular Dichroism analyses reveal that the overall structure of the protein is not altered upon interaction with the metal compound. These results suggest that BLG could act as a carrier for anticancer metallodrugs and open the way for a rational design of new biomaterials based on metallodrug/β-lactoglobulin adduct nanoparticles. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-041757 | Protein nanocages for anticancer metal-based drug delivery | , |
Show Abstract |
||||||||||||||||||||||||||||||||||||||
Supramolecular protein assembly, such as cages, rings, and tubes can be used as reaction vessels and molecular templates for applications in catalysis, imaging and drug delivery.1 Ferritin (Ft) is a member of ferroxidase family of enzymes that forms a spherical nanocage. It sequesters iron by concentrating it in its internal cavity for storage and detoxification.2 Ft is very promising as a drug loading and releasing system since it is non-immunogenic, bio-compatible, highly stable, soluble in the bloodstream. It can be internalized via Ft-binding receptors (like transferrin receptor 13 or Scara54) that are over-expressed in a variety of malignant cells. Well established metallodrugs like cisplatin,5 carboplatin,6 a Pt-terpyridine compound,7 three different gold-based anticancer compounds (Auoxo3, Au2phen, Auoxo4),8-9 a bimetallic Pt-Au compound10, a bimetallic Pt-As compound and a di-ruthenium complex11 have been trapped within the Ft nanocages, taking advantage of the alkaline pH disassembly/reassembly protocol. The drug-loaded nanocomposites have been characterized by circular dichroism, to evaluate the protein secondary structure content upon drug encapsulation, and by UV-vis absorption spectroscopy, to assess the drug loading within the protein cage. ICP-MS allowed to quantify the amount of drug trapped inside the nanocage and to define metal/Ft stoichiometry, while X-ray crystallography unveiled the metallodrugs binding sites on the proteins structure and the nature of the interaction of the different compounds with Ft. The compounds often degrade upon encapsulation within the protein cage; metal-containing fragments coordinate Cys or His side chains. However, the coordination does not affect the overall cytotoxicity of the encapsulated anticancer agents, since many molecules of the metallodrugs remain trapped in the bulk within the inner core of the cage. Biological activity studies show that, even though the presence of the cage reduces the overall toxicity of the metallodrugs, the adducts of the selected compounds with Ft are generally more selective towards cancer cells than to non-malignant cells. Altogether these data indicate that encapsulation of metal-based drugs within Ft nanocages is a promising strategy to deliver these molecules to their final targets.12
|
|||||||||||||||||||||||||||||||||||||||||
sciforum-043888 | Assessment of essential oil-loaded nanofibrous mats against the Escherichia virus MS2, a mimetic of SARS-CoV-2, for potential applications as inner layers in individual protection masks | , , , |
Show Abstract |
||||||||||||||||||||||||||||||||||||||
In December 2019, a novel strain of coronavirus, SARS-CoV-2, was identified. Infected patients revealed symptoms of fever, cough (dry), sore throat, and fatigue, which began manifesting after 5 days of incubation. Hoping to prevent transmission, many countries adopted a mandatory mask use in closed public spaces. However, most mask options display a passive action against COVID-19. To overcome such restrictions, this work proposes the incorporation of anti-viral essential oils (EOs) loaded onto a nanofibrous layer that can be adapted to both community and commercial masks. Twenty EOs selected based on their antimicrobial nature were examined for the first time against the Escherichia virus MS2. The most effective were the lemongrass (LO), Niaouli (NO) and eucalyptus (ELO) with a minimum inhibitory concentration (MIC) of 356.0 mg/mL, 365.2 mg/mL and 586.0 mg/mL, respectively. Polycaprolactone (PCL) and cellulose acetate (CA) were prepared individually at 14 wt% in chloroform/dimethylformamide (DMF) and 10 wt% in acetone/DMF, respectively, and combined at 3:1 ratio. Polymeric solutions were then processed via eletrospinning with processing parameters being optimized to 24.7 kV, 3.2 mL/h and 21 cm. Uniform, beadless nanofibers were obtained. Mats were characterized as mechanically resilient, to endure movements arising from mask positioning, and hydrophobic in nature, to repel droplets coming from the exterior. Loading of the nanofibrous mats was accomplished via physisorption using the free -OH groups of the CA as linkers. Mats were loaded with the EOs at MIC concentration for 72 h (saturation). Presence of the EOs was confirmed along the mats. Antimicrobial testing via halo determination, verified their diffusion abilities. More importantly, time-kill kinetics testing of the loaded mats attested to the EOs capability to fight the virus MS2 even when bonded to the nanofibers. Data demonstrated the potential of these EOs-loaded PCL/CA nanofibers mats to work as COVID-19 active barriers for individual protection masks. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-044013 | Hydrogel-like films modified with cinnamon leaf oil: a new scaffolding system capable of inhibiting Pseudomonas aeruginosa bacteria | , , , |
Show Abstract |
||||||||||||||||||||||||||||||||||||||
Pseudomonas aeruginosa is considered a pathogen with clinical relevance, due to its intrinsic antibiotic resistance. For this reason, it is crucial to think of alternatives to treat P. aeruginosa-derived infections. Essential oils (EOs), natural products, possessing anti-inflammatory, antiseptic and analgesic properties, have been applied in this aim. Yet due to their volatile nature, polymeric microcapsules are frequently engineered to incorporate the antimicrobial agents at the core and work as drug carriers. As the result, the microcapsules protect the antimicrobial agents from the surrounding environment and, consequently, prevent undesirable effects, such as early degradation. In this study, a delivery platform for a controlled release of cinnamon leaf oil (CLO) was developed, resorting to chitosan (CS)/tripolyphosphate (TPP) microcapsules embedded in a hydrogel-like matrix. CS microcapsules were produced without any pH adjustment (CS1) and with pH adjusted to 5.0 (CS4). Subsequently, the microcapsules were incorporated within sodium alginate (SA) and gelatin (GN) hydrogel-like films, prepared by the solvent casting-phase inversion method. SA and GN were selected since SA presents a fast ionic gelation with divalent cations and GN has a good biodegradability. Fourier-transform infrared spectroscopy analysis confirmed the effective incorporation of CS microcapsules with CLO within the SA/GN films. A continuous release of the entrapped CLO was achieved. In addition, a matched time kill kinetics against the bacteria was attained, and the SA/GN/CS1 films were determined more efficient. Data revelated the outstanding potential of CLO loaded films for the inhibition of P. aeruginosa. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-044805 | Probiotics administration ameliorate azoxymethane induced-carcinogenesis by reducing the formation of aberrant crypt foci and modulation oxidative stress in rats | , , , |
Show Abstract |
||||||||||||||||||||||||||||||||||||||
BACKGROUND/AIM: Aberrant crypt foci (ACF) are early lesions in the neoplastic induction found in the rat colon of the carcinogenic model. ACF is one of the first changes in the colon that lead to colorectal cancer (CRC). Probiotics and fermented foods are well known for their beneficial role in gut health and previous studies showed their therapeutic effects on gastrointestinal diseases. The aim of this study is to investigate the preventive role of Propionibacterium freudenreichii and Faecalibacterium prausnitzii probiotics against CRC Induction in rats treated with azoxymethane (AOM). METHODS: Rats were injected subcutaneously with 7mg/kg of AOM once a week for 3 weeks, and probiotics (P. freundreichii and F. prausnitzii) were administered orally at 1×109 CFU/ml once a day for 6 weeks. 5- Fluorouracil (5-FU) as a reference anti-cancer drug was administered intraperitoneally at 35mg/kg 3 times a week for 6 weeks. After the treatment period, the colon of the rats was harvested and examined microscopically and histologically. Lipid peroxidation levels in colon tissues were measured using malondialdehyde (MDA) assay. RESULT: Microscopical examination of harvested rat colons after methylene blue staining showed that the total number and multiplicity of ACF were significantly lower in the probiotics groups (p < 0.05) than the AOM control group that did not receive any intervention. Histological examination of the colon showed increased severe hyperplasia and dysplasia of the ACF in the AOM group compared to the treatment groups. Probiotics administration also reduced the levels of MDA in the colon of the rats compared to the rats in the AOM control group CONCLUSION: These results suggest that probiotics play a preventive role in CRC initiation and development by slowing down ACF formation, reducing the severity of ACF lesions, and reducing lipid peroxidation levels in the colon. |
Instructions for Authors
Submissions should be submitted by the authors online by registering at https://ecb2021.sciforum.net/, and using the “Submit Abstract” function once logged into system.
- Scholars interested in participating with the conference can submit their abstract (about 200–250 words covering the areas of manuscripts for the proceedings issue) online at this website up to 16 March 2021.
- The Conference Committee will conduct a pre-evaluation, based on the submitted abstract, of whether the contribution from the authors of the abstract will be welcome for the 1st International Electronic Conference on Biomedicine. All authors will be notified by 31 March 2021 about the acceptance of their abstract.
- If the abstract is accepted for this conference, the author is asked to submit the manuscript optionally along with a PowerPoint and/or video presentation of his/her paper (only PDF), up to the submission deadline of 30 April 2021.
- The conference proceedings papers and presentations will be available at https://ecb2021.sciforum.net for discussion during the time of the conference, 1–26 June 2021, and will be published in Journal Proceedings.
- After the conference, the authors are encouraged to submit a full manuscript based on the proceedings to the Biomedicines Special Issue "Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)" with a 20% discount on the Article Processing Charges.
Manuscripts for the proceedings issue must have the following organization:
First page:
- Title
- Full author names
- Affiliations (including full postal address) and authors’ e-mail addresses
- Abstract (200–250 words)
- Keywords
- Introduction
- Methods
- Results and Discussion
- Conclusions
- (Acknowledgements)
- References
Manuscripts should be prepared in MS Word or any other word processor and should be converted to PDF format before submission. The publication format will be PDF. The manuscript should be at least 3 pages (incl. figures, tables, and references) and should not exceed 6 pages.
Presentation Slides
Authors are encouraged to prepare a presentation in PowerPoint or similar software, to be displayed online along with the manuscript. Slides, if available, will be displayed directly in the website using the proprietary slides viewer at Sciforum.net. Slides can be prepared in exactly the same way as for any traditional conference where research results can be presented. Slides should be converted to PDF format before submission so that we can easily and automatically process them for online display.
Video Presentations
Besides their active participation within the forum, authors are also encouraged to submit video presentations. The video should be no longer than 20 minutes and be prepared in one of the following formats:
- MOV
- MPEG4
- MP4
- AVI
- WMV
- MPEGPS
- FLV
Authors that wish to present only a poster, i.e., without a proceedings paper, can do so in section I. Posters will be available on the conference website during and after the event. Similarly to papers presented at the conference, participants will be able to ask questions and make comments about the posters. Posters that are submitted without a paper will not be included in the proceedings of the conference.
Submission: Manuscripts should be submitted online at https://ecb2021.sciforum.net by registering and logging in to this website.
Accepted File Formats
- MS Word: Manuscript prepared in MS Word must be converted into a single file before submission. When preparing manuscripts in MS Word, the 1st International Electronic Conference on Microbiology Microsoft Word template file (see download below) must be used. Please do not insert any graphics (schemes, figures, etc.) into a movable frame which can superimpose the text and make layout very difficult.
1st International Electronic Conference on Biomedicine Microsoft Word template file
Manuscript Preparation
- Paper Format: A4 paper format, the printing area is 17.5 cm × 26.2 cm. The margins should be 1.75 cm on each side of the paper (top, bottom, left, and right sides).
- Paper Length: The conference proceedings paper should not be longer than 6 pages. The conference manuscript should be as concise as possible.
- Formatting/Style: The paper style of the journal Proceedings should be followed. You may download the template file to prepare your paper (see above). The full titles of the cited papers must be given. Reference numbers should be placed in square brackets [ ], and placed before punctuation; for example [4] or [1–3], and all the references should be listed separately and as the last section at the end of the manuscript.
- Authors List and Affiliation Format: Authors’ full first and last names must be given. Abbreviated middle name(s) can be added. For papers written by various contributors, a corresponding author must be designated. The PubMed/MEDLINE format is used for affiliations: complete street address information including city, zip code, state/province, country, and email address should be added. All authors who contributed significantly to the manuscript (including writing a section) should be listed on the first page of the manuscript, below the title of the article. Other parties who provided only minor contributions should only be listed under Acknowledgments. A minor contribution might be a discussion with the author, reading through the draft of the manuscript, or performing English corrections.
- Figures, Schemes, and Tables: Authors are encouraged to prepare figures and schemes in color. Full color graphics will be published free of charge. Figure and schemes must be numbered (Figure 1, Scheme I, Figure 2, Scheme II, etc.) and an explanatory title must be added. Tables should be inserted into the main text, and numbers and titles for all tables supplied. All table columns should have an explanatory heading. Please supply legends for all figures, schemes, and tables. The legends should be prepared as a separate paragraph of the main text and placed in the main text before a table, figure, or scheme.
Potential Conflicts of Interest
It is the authors’ responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state here “The authors declare no conflict of interest”. This should be conveyed in a separate “Conflict of Interest” statement preceding the “Acknowledgments” and “References” sections at the end of the manuscript. Financial support for the study must be fully disclosed under the “Acknowledgments” section.
Copyright
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their scholarly works. Hence, by submitting a Communication paper to this conference, you retain the copyright of your paper, but you grant MDPI the non-exclusive right to publish this paper online on the Sciforum.net platform. This means you can easily submit your paper to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).
Call for Papers
The 1st International Electronic Conference on Biomedicine will be held on 1–26 June 2021. ECB 2021 aims to promote and advance the exciting and rapidly changing field of Biomedicine. All proceedings will be held online at https://ecb2021.sciforum.net.
Topics of interest include, but are not limited to:
- Nanomedicine and Precision Medicine
- Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
- Cancer Therapeutics
- Metal-based Therapeutics in Preclinical and Clinical Developments
- Oncolytic Virus-mediated Immunotherapy
- Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
- Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
- Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
- Translational Biomarkers in Clinical Biomedicine and Precision Medicine
- G-protein-coupled Receptor Family
- Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
ECB 2021 is an electronic conference sponsored by Biomedicines. Participation is free of charge for authors and attendees. Accepted papers will be gathered in the proceedings of the conference. Selected extended versions of the papers will be published in a Special Issue of Biomedicines and undergo full peer review (ISSN 2227-9059; impact factor: 4.717 (2020)) with a 20% discount on the article processing charge. ECB 2021 offers you the opportunity to participate in this international, scholarly conference without the concerns or expenditure of travel—all you need is your computer and access to the internet. We would like to invite you to attend this conference and present your latest work.
Abstracts (in English) should be submitted online by 16 March 2021 at https://ecb2021.sciforum.net. For accepted abstracts, the proceedings can be submitted by 30 April 2021. The conference will be held on 1–26 June 2021.
Paper Submission Guidelines
For information about the submission procedure and preparation of a full presentation, please refer to the "Instructions for Authors".
Time Schedule
- Abstract Submission: 16 March 2021
- Notification of Acceptance: 31 March 2021
- Paper Submission Deadline: 30 April 2021
- Conference Open: 1–26 June 2021
We thank you in advance for your attendance of this conference and look forward to a stimulating exchange.
Event Awards
To acknowledge the support of the conference esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to launch the Best Paper Award and Best Poster Award.
The Awards
Number of Awards Available: 1
The Best Paper Award is presented to the paper judged to make the most significant contribution to the conference.Number of Awards Available: 1
The Best Poster Award was established to recognize the scientific merit exhibited in poster presentation and preparation.Terms and Conditions:
Best Paper Award
As a sponsor, Biomedicines would like to award the best paper as elected by the conference committee. The award will consist of 500 Swiss Francs. We look forward to posting your contributions.
Criteria for Evaluation of Best Paper Award:
- Full paper must be submitted to ECB2021;
- Originality/novelty of the paper;
- Significance of content;
- Scientific soundness;
- Interest to the readers;
- English language and style.
Evaluation
- Each Evaluation Committee member will give an assessment for each applicant in terms of the criteria outlined above;
- The total score for each presentation will be ranked from highest to lowest;
- If two or more authors receive the same score, further evaluation will be carried out;
- All decisions made by the Evaluation Committee are final.
Best Poster Award
As a sponsor, Biomedicines would like to grant an award (500 Swiss Francs) for the best poster presented at the conference. This prize is awarded by a jury to the best designed poster presented at the conference.
Posters should have the following information.
- Title (with authors and affiliations)
- Introduction/Objectives/Aims
- Methods
- Results
- Conclusion
- References
- Acknowledgements
- Contact information
- A 3-minute video presentation
During the conference, the chair is invited to judge the quality of the 3-minute video presentation and poster. Criteria for judgement of the presentation will be the ability to summarize the content of the work and motivate the interest in looking at the poster. In addition, the clarity of poster and appearance quality will be considered.
S1. Nanomedicine and Precision Medicine
Show all published submissions (6) Hide published submissions (6)
Submissions
List of Papers (6) Toggle list
S2. Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
S4. Metal-based Therapeutics in Preclinical and Clinical Developments
Session Chair
Dr. Muhammad Hanif, The University of Auckland, Auckland, New Zealand
S6. Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
Show all published submissions (1) Hide published submissions (1)
Submissions
List of Papers (1) Toggle list
S7. Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
S8. Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
S9. Translational Biomarkers in Clinical Biomedicine and Precision Medicine
S10. G-protein-coupled Receptor Family
Show all published submissions (7) Hide published submissions (7)
Submissions
List of Papers (7) Toggle list